Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Deepak M W Balak

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Dermatology (Basel, Switzerland)|May 13, 2022
Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-AnalysisJuliëtte N Pouw, Marleen E Jacobs, Deepak M W Balak, et al.
BMC Neurology|October 18, 2013
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional studyDeepak M W Balak, Gerald J D Hengstman, Enes Hajdarbegovic, et al.
Clinical Kidney Journal|January 23, 2016
Drug-induced Fanconi syndrome associated with fumaric acid esters treatment for psoriasis: a case seriesDeepak M W Balak, Jan Nico Bouwes Bavinck, Aiko P J de Vries, et al.
The Journal of Dermatological Treatment|January 16, 2020
Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countriesDeepak M W Balak, Jose-Manuel Carrascosa, Stamatis Gregoriou, et al.
The Journal of Investigative Dermatology|November 28, 2021
Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature ReviewDeepak M W Balak, Lourdes M Perez-Chada, Lisa N Guo, et al.
Clinical Immunology (Orlando, Fla.)|November 24, 2016
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasisDeepak M W Balak, Martijn B A van Doorn, Robert D Arbeit, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 15, 2019
Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatmentDaphne S Bakker, Julia Drylewicz, Stefan Nierkens, et al.
Dermatology (Basel, Switzerland)|September 1, 2016
Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory StudyJi Sun van Bezooijen, Deepak M W Balak, Martijn B A van Doorn, et al.
JAAD International|February 3, 2026
Remote monitoring in chronic immune-mediated inflammatory diseases: A systematic review of active and passive approachesMariona Oliver, Jannik Rousel, Jan W Schoones, et al.
Journal of the American Academy of Dermatology|June 13, 2026
AI-Powered Imaging for Objective Psoriasis Severity Assessment at Home: Feasibility and Reliability in a Randomized Clinical TrialMariona Oliver, Monika Molnarova, Menthe Bergmans, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Dermatology (Basel, Switzerland)|May 13, 2022
Do Patients with Psoriatic Arthritis Have More Severe Skin Disease than Patients with Psoriasis Only? A Systematic Review and Meta-AnalysisJuliëtte N Pouw, Marleen E Jacobs, Deepak M W Balak, et al.
BMC Neurology|October 18, 2013
Prevalence of cutaneous adverse events associated with long-term disease-modifying therapy and their impact on health-related quality of life in patients with multiple sclerosis: a cross-sectional studyDeepak M W Balak, Gerald J D Hengstman, Enes Hajdarbegovic, et al.
Clinical Kidney Journal|January 23, 2016
Drug-induced Fanconi syndrome associated with fumaric acid esters treatment for psoriasis: a case seriesDeepak M W Balak, Jan Nico Bouwes Bavinck, Aiko P J de Vries, et al.
The Journal of Dermatological Treatment|January 16, 2020
Cost per PASI-75 responder of calcipotriol plus betamethasone dipropionate cutaneous foam versus nonbiologic systemic therapies for the treatment of plaque psoriasis in seven European countriesDeepak M W Balak, Jose-Manuel Carrascosa, Stamatis Gregoriou, et al.
The Journal of Investigative Dermatology|November 28, 2021
Defining Psoriasis Remission Based on Histopathologic and Molecular Criteria: A Systematic Literature ReviewDeepak M W Balak, Lourdes M Perez-Chada, Lisa N Guo, et al.
Clinical Immunology (Orlando, Fla.)|November 24, 2016
IMO-8400, a toll-like receptor 7, 8, and 9 antagonist, demonstrates clinical activity in a phase 2a, randomized, placebo-controlled trial in patients with moderate-to-severe plaque psoriasisDeepak M W Balak, Martijn B A van Doorn, Robert D Arbeit, et al.
Clinical and Experimental Allergy : Journal of the British Society for Allergy and Clinical Immunology|September 15, 2019
Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatmentDaphne S Bakker, Julia Drylewicz, Stefan Nierkens, et al.
Dermatology (Basel, Switzerland)|September 1, 2016
Combination Therapy of Etanercept and Fumarates versus Etanercept Monotherapy in Psoriasis: A Randomized Exploratory StudyJi Sun van Bezooijen, Deepak M W Balak, Martijn B A van Doorn, et al.
JAAD International|February 3, 2026
Remote monitoring in chronic immune-mediated inflammatory diseases: A systematic review of active and passive approachesMariona Oliver, Jannik Rousel, Jan W Schoones, et al.
Journal of the American Academy of Dermatology|June 13, 2026
AI-Powered Imaging for Objective Psoriasis Severity Assessment at Home: Feasibility and Reliability in a Randomized Clinical TrialMariona Oliver, Monika Molnarova, Menthe Bergmans, et al.
Pageof 4